GNR-084 / Generium - LARVOL DELTA

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: AO GENERIUM | Trial completion date: Jun 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2023 ➔ Feb 2025

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: AO GENERIUM | Trial completion date: Jun 2023 ➔ Jun 2024 | Trial primary completion date: Jun 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CCR7 • CD19 • CD20 • PTPRC

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL (clinicaltrials.gov) - P1/2; N=36; Recruiting; Sponsor: AO GENERIUM; Trial primary completion date: Jun 2021 ➔ Jun 2023

Clinical • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CCR7 • CD19 • CD20 • PTPRC

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL (clinicaltrials.gov) - P1/2; N=36; Recruiting; Sponsor: AO GENERIUM

Clinical • New P1/2 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology